Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,030.00. The ...
Zacks.com on MSN6d
Regeneron to Report Q4 Earnings: Is a Beat in the Cards?Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...
To counter the decline in Eylea sales, Regeneron developed a higher dose ... which currently comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma ...
Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...
Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
The upcoming report from Regeneron (REGN) is expected to reveal ... The combined assessment of analysts suggests that 'Revenues- Libtayo- Total' will likely reach $338.92 million.
The upcoming report from Regeneron (REGN) is expected to reveal quarterly earnings ... The combined assessment of analysts suggests that 'Revenues- Libtayo- Total' will likely reach $338.92 million.
Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback